Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
Interventions: Not listed
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2029
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Peripheral Vascular Disease, Hemorrhage
Interventions: EVICEL ™ Fibrin Sealant (Human); Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Whole Genome Sequencing, Myelodysplastic Syndromes
Interventions: ChromoSeq; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Interventions: Blood Specimen; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Philadelphia, Pennsylvania + 1 more

Conditions: Blood Loss, Surgical
Interventions: Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel); Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: Not listed
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more

Conditions: Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
Interventions: Biomarkers of inflammation; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 3,402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Osteoarthritis, Hip, Blood Loss
Interventions: Werewolf Fastseal 6.0; Device
Lead sponsor: North Texas Medical Research Institute, PLLC; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Rockwall, Texas • Rowlett, Texas

Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Interventions: chemoprotection, complementary or alternative medicine procedure, management of therapy complications; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide, Ramipril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Prostate Arterial Embolization; Device
Lead sponsor: Antonios Likourezos; Other
Eligibility: 35 Years to 99 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Head and Neck Cancer
Interventions: Blood collection, Saliva collection, Tissue collection, Surveys; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hemophilia, Bone Disease
Interventions: Advate; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 16 Years to 85 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Androgenetic Alopecia
Interventions: Platelet rich plasma; Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Heart Failure, Cardiac Failure, Congestive Heart Failure, Heart Failure, Left-sided
Interventions: HeartAssist 5® VAD System, Control VAD; Device
Lead sponsor: ReliantHeart Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 14
States / cities: San Francisco, California • Stanford, California • Coral Gables, Florida + 8 more

Conditions: Pancreatic Cancer
Interventions: Blood Sample Collection, Tissue Sample Collection, Data Collection, Medical Image Collection; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Jackson, Mississippi

Conditions: Primary Ciliary Dyskinesia, Healthy
Interventions: Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 6 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Intracranial Hypertension
Interventions: HS-1000 recording; Device
Lead sponsor: HeadSense Medical; Industry
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Knee Meniscus Tear
Interventions: BioDuct Meniscal Repair Device; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Indianapolis, Indiana • Salisbury, Maryland • Memphis, Tennessee

Conditions: Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, Myocarditis, ICI-Myocarditis, Solid Malignant Tumor, Hematologic Malignancy, Subclinical Myocarditis, Subclinical ICI-myocarditis
Interventions: Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Vectra MBDA Test; Genetic
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Annapolis, Maryland • Baltimore, Maryland • Catonsville, Maryland + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30; Drug · Procedure · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chimerism, Blood Transfusion, Wounds and Injuries
Interventions: Not listed
Lead sponsor: Vitalant Research Institute; Other
Eligibility: 12 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry

The Evicel Post-Authorization Surveillance Study

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

Bipolar Sealer for Reduction of Blood Loss in Anterior Total Hip Arthroplasties

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

Transdisciplinary Oral/Oropharyngeal Cancer Research & Care in Head and Neck Cancer (TORCH)

Prospective Biomarkers of Bone Metabolism in Hemophilia A

The Utility of Platelet Rich Plasma in Hair Loss

Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

Denosumab for Type 1 Diabetes

Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients

A Prospective, Post-market, Multi-center Feasibility Study of the BioDuct® Meniscal Repair Device

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury